MICHAEL HOLLIDAY to Hyperinsulinism
This is a "connection" page, showing publications MICHAEL HOLLIDAY has written about Hyperinsulinism.
Connection Strength
0.232
-
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Ka Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Cancer Discov. 2024 Feb 08; 14(2):240-257.
Score: 0.232